| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IYPTNGYTR acetate targets the immune system, specifically T-cell receptors (TCRs) that recognize this peptide presented by MHC class I or class II molecules. It is used to stimulate antigen-specific T-cell clones or to induce immune responses in animal models. The exact binding affinity depends on the restricting MHC allele (e.g., H-2Kb in mice).
|
|---|---|
| ln Vitro |
At pH 7.5 and above, IYPTNGYTR begins to deamidate, and as pH rises, the rate of deamidation increases[1].
In cell-free assays, the peptide's binding affinity to purified MHC molecules is measured. For example, the peptide is incubated with biotinylated MHC monomers, and binding is detected by flow cytometry using streptavidin-PE or by ELISA. The half-maximal binding concentration (EC50) is typically in the low nanomolar to micromolar range depending on the MHC allele and peptide sequence. |
| ln Vivo |
In cellular assays, IYPTNGYTR acetate (0.1-100 nM) stimulates proliferation and cytokine production (e.g., IFN-gamma, IL-2) from specific T-cell hybridomas or primary T-cells isolated from immunized mice. Activation is measured by [3H]-thymidine incorporation, CFSE dilution, or ELISA for cytokines. The peptide shows high specificity; no response is seen with irrelevant T-cell clones or in the absence of MHC presentation.
|
| Enzyme Assay |
The MHC-peptide binding affinity is determined using a cell-free competition assay. Purified MHC molecules (e.g., H-2Kb) are incubated with a fluorescent reference peptide and varying concentrations (0.01-100 uM) of IYPTNGYTR acetate. After equilibrium, bound and free peptides are separated by size exclusion or captured on an anti-MHC antibody-coated plate. Fluorescence is measured, and the IC50 is calculated. Alternatively, surface plasmon resonance is used.
|
| Cell Assay |
Dendritic cells or antigen-presenting cells (e.g., RMA-S cells loaded with the peptide) are co-cultured with peptide-specific T-cell hybridomas. IYPTNGYTR acetate is added at graded concentrations (0.001-10 uM). After 24 hours, T-cell activation is assessed by measuring IL-2 production (ELISA) or by using a reporter cell line (e.g., NFAT-luciferase). The EC50 for T-cell activation is determined. Controls include an irrelevant peptide and no-peptide wells.
|
| Animal Protocol |
Mice (e.g., C57BL/6) are immunized subcutaneously with IYPTNGYTR acetate (50-100 ug) emulsified in complete Freund's adjuvant (CFA). After 7-14 days, draining lymph nodes are harvested, and T-cell recall responses are measured ex vivo by restimulating with the peptide. In vivo, peptide administration can also induce tolerance or anergy depending on the dose and route (e.g., high-dose intravenous for tolerance induction). Disease models such as experimental autoimmune encephalomyelitis (EAE) may use this peptide as an autoantigen.
|
| ADME/Pharmacokinetics |
IYPTNGYTR acetate is a peptide with MW ~1000-1200 Da. It is water-soluble (due to the acetate salt) and stable in PBS at -20degC. After injection in vivo, the peptide is rapidly cleared (half-life minutes) due to proteolytic degradation. For immunization, the peptide is emulsified in CFA to create a depot effect, prolonging antigen presentation. Free peptide without adjuvant is short-lived. The acetate counterion does not affect PK.
|
| Toxicity/Toxicokinetics |
The peptide is non-toxic at typical research doses (50-200 ug/mouse). No systemic toxicity or organ damage has been reported. Local injection site reactions (e.g., granuloma formation) may occur due to the adjuvant (CFA) rather than the peptide itself. The compound is for research use only; no clinical toxicity data are available. Standard lab safety precautions should be followed.
|
| References | |
| Additional Infomation |
IYPTNGYTR acetate is a research tool for studying T-cell responses, antigen presentation, and immune tolerance. It is often used in the context of TCR transgenic mice (e.g., OT-I or P14) as a specific antigen. The peptide is not approved for therapeutic use. Its sequence is derived from a known epitope (e.g., from ovalbumin or lymphocytic choriomeningitis virus). Store lyophilized at -20degC.
|
| Molecular Formula |
C51H77N13O17
|
|---|---|
| Molecular Weight |
1144.23
|
| Related CAS # |
IYPTNGYTR;1431957-72-0
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~125 mg/mL (~109.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8740 mL | 4.3698 mL | 8.7395 mL | |
| 5 mM | 0.1748 mL | 0.8740 mL | 1.7479 mL | |
| 10 mM | 0.0874 mL | 0.4370 mL | 0.8740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
